OBJECTIVE: To study clinical, immunologic, and virologic outcomes in patients who stop antiretroviral therapy (ART) with relatively preserved CD4 cell counts. DESIGN AND METHODS: Patients with a documented CD4 cell count >250 cells/microL who stopped ART for any reason for at least 5 weeks were studied. Relevant clinical and laboratory data were collected using a standardized data collection form. MAIN OUTCOME MEASURES: Patients were monitored for outcomes including Centers for Disease Control (CDC) category B or C events, time to restarting ART, and time to reaching a CD4 cell count of < or = 250 cells/microL. RESULTS: A total of 107 patients were included. The median time on ART was 45 months and median number of antiretroviral medications was 4. The median pre-ART CD4 cell count and HIV viral load were 463 cells/microL and 4.35 log copies/mL, respectively. The median CD4 cell at time of ART stop was 739 cell/microL. The slope of the CD4 decrease was 65 cells/mo in the first 2 months, which was greater than the subsequent decline of 8 cells/mo thereafter (P < 0.01). Similarly the median viral load increase was 2.54 log copies/mL in the first 2 months after stopping and was unchanged after that point. Two patients experienced the retroviral rebound syndrome after ART cessation but no CDC category B or C events were observed during 10 months of follow-up. The median time from stopping ART to reaching the combined endpoint of CD4 <250 or restarting ART was 8.9 months. In multivariate analysis, pre-ART CD4 cell count >250 was protective of reaching the combined endpoint (odds ratio = 0.156, P = 0.03). Other predictors of reaching the combined endpoint in multivariate analysis were older age and number of prior ART agents. Patients who restarted ART had a favorable virologic and immunologic response. CONCLUSIONS: Patients with relatively high CD4 cell counts prior to starting ART did well after stopping ART. Pre-ART CD4 cell count can be used to predict outcomes after ART cessation.
OBJECTIVE: To study clinical, immunologic, and virologic outcomes in patients who stop antiretroviral therapy (ART) with relatively preserved CD4 cell counts. DESIGN AND METHODS: Patients with a documented CD4 cell count >250 cells/microL who stopped ART for any reason for at least 5 weeks were studied. Relevant clinical and laboratory data were collected using a standardized data collection form. MAIN OUTCOME MEASURES: Patients were monitored for outcomes including Centers for Disease Control (CDC) category B or C events, time to restarting ART, and time to reaching a CD4 cell count of < or = 250 cells/microL. RESULTS: A total of 107 patients were included. The median time on ART was 45 months and median number of antiretroviral medications was 4. The median pre-ARTCD4 cell count and HIV viral load were 463 cells/microL and 4.35 log copies/mL, respectively. The median CD4 cell at time of ART stop was 739 cell/microL. The slope of the CD4 decrease was 65 cells/mo in the first 2 months, which was greater than the subsequent decline of 8 cells/mo thereafter (P < 0.01). Similarly the median viral load increase was 2.54 log copies/mL in the first 2 months after stopping and was unchanged after that point. Two patients experienced the retroviral rebound syndrome after ART cessation but no CDC category B or C events were observed during 10 months of follow-up. The median time from stopping ART to reaching the combined endpoint of CD4 <250 or restarting ART was 8.9 months. In multivariate analysis, pre-ARTCD4 cell count >250 was protective of reaching the combined endpoint (odds ratio = 0.156, P = 0.03). Other predictors of reaching the combined endpoint in multivariate analysis were older age and number of prior ART agents. Patients who restarted ART had a favorable virologic and immunologic response. CONCLUSIONS:Patients with relatively high CD4 cell counts prior to starting ART did well after stopping ART. Pre-ARTCD4 cell count can be used to predict outcomes after ART cessation.
Authors: Matthew J Perkins; William P Bradley; Tahaniyat Lalani; Brian K Agan; Timothy J Whitman; Tomas M Ferguson; Jason F Okulicz; Anuradha Ganesan Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.731
Authors: José M Martinez-Navio; Núria Climent; Rodrigo Pacheco; Felipe Garcia; Montserrat Plana; Meritxell Nomdedeu; Harold Oliva; Cristina Rovira; Laia Miralles; José M Gatell; Teresa Gallart; Josefa Mallol; Carme Lluis; Rafael Franco Journal: Immunology Date: 2009-11 Impact factor: 7.397
Authors: Koen K A Van Rompay; Kristin A Trott; Kartika Jayashankar; Yongzhi Geng; Celia C LaBranche; Jeffrey A Johnson; Gary Landucci; Jonathan Lipscomb; Ross P Tarara; Don R Canfield; Walid Heneine; Donald N Forthal; David Montefiori; Kristina Abel Journal: Retrovirology Date: 2012-07-17 Impact factor: 4.602
Authors: Ellen Van Gulck; Leo Heyndrickx; Lotte Bracke; Sandra Coppens; Eric Florence; Anne Buvé; Paul Lewi; Guido Vanham Journal: AIDS Res Ther Date: 2011-02-11 Impact factor: 2.250
Authors: Ellen Van Gulck; Lotte Bracke; Leo Heyndrickx; Sandra Coppens; Derek Atkinson; Céline Merlin; Alexander Pasternak; Eric Florence; Guido Vanham Journal: PLoS One Date: 2012-05-30 Impact factor: 3.240